Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
09 2023
Historique:
received: 30 06 2023
accepted: 03 07 2023
pmc-release: 01 09 2024
medline: 18 8 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children' Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.

Identifiants

pubmed: 37449925
doi: 10.1002/pbc.30565
pmc: PMC10577684
mid: NIHMS1930821
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e30565

Subventions

Organisme : NCI NIH HHS
ID : R01 CA154947
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Leukemia. 2013 Feb;27(2):416-22
pubmed: 22907048
J Clin Oncol. 2019 Dec 1;37(34):3291-3299
pubmed: 31609651
Pediatr Blood Cancer. 2014 Mar;61(3):479-87
pubmed: 24106153
Pediatr Blood Cancer. 2013 Jun;60(6):979-84
pubmed: 23255391
J Clin Oncol. 2023 Apr 10;41(11):2043-2053
pubmed: 36534942
Blood. 2021 Apr 1;137(13):1777-1791
pubmed: 33075814
J Clin Oncol. 2021 Nov 20;39(33):3716-3724
pubmed: 34570655
Blood. 2000 Dec 1;96(12):3681-95
pubmed: 11090048
Blood. 2020 Apr 16;135(16):1319-1331
pubmed: 32106306
J Clin Oncol. 2009 Jul 20;27(21):3533-9
pubmed: 19546402
N Engl J Med. 2020 Jun 4;382(23):2207-2219
pubmed: 32492302
N Engl J Med. 2022 Sep 22;387(12):1111-1122
pubmed: 36129999
Blood. 2001 Jun 15;97(12):3699-706
pubmed: 11389005
Br J Haematol. 2015 Apr;169(2):299-301
pubmed: 25400231
J Clin Oncol. 2009 Feb 20;27(6):897-903
pubmed: 19139435
Eur J Cancer. 2005 Nov;41(17):2682-9
pubmed: 16291085
Pediatr Blood Cancer. 2012 Nov;59(5):828-33
pubmed: 22389307
J Clin Oncol. 2019 Nov 1;37(31):2857-2865
pubmed: 31513482
Haematologica. 2016 Dec;101(12):1581-1591
pubmed: 27515251
Blood Adv. 2020 Aug 25;4(16):4007-4019
pubmed: 32841337
Blood. 2019 Sep 5;134(10):802-813
pubmed: 31292115
J Exp Med. 2014 Apr 7;211(4):669-83
pubmed: 24638167
Blood Adv. 2023 Feb 28;7(4):602-610
pubmed: 36541957
Pediatr Blood Cancer. 2020 Aug;67(8):e28416
pubmed: 32452165
J Clin Oncol. 2019 Nov 20;37(33):3081-3089
pubmed: 31398081
Blood. 2013 Jan 10;121(2):278-85
pubmed: 23149845
Br J Haematol. 2020 Jun;189(5):826-843
pubmed: 32141616
Pediatr Blood Cancer. 2016 May;63(5):794-800
pubmed: 26728447
Nat Genet. 2018 Dec;50(12):1650-1657
pubmed: 30374066
Am J Transplant. 2012 Nov;12(11):3069-75
pubmed: 22883417
Lancet Oncol. 2022 Jan;23(1):27-52
pubmed: 34871551
Blood. 2019 Apr 11;133(15):1691-1694
pubmed: 30718231
Nat Med. 2021 May;27(5):851-861
pubmed: 33958797
Pediatr Pulmonol. 2020 Aug;55(8):2074-2081
pubmed: 32511892
Blood. 2022 Aug 4;140(5):419-437
pubmed: 34758074
J Clin Oncol. 1989 Feb;7(2):186-93
pubmed: 2915234
Nature. 2019 Mar;567(7749):521-524
pubmed: 30867592
Pediatr Blood Cancer. 2014 Dec;61(12):2236-42
pubmed: 25156886
N Engl J Med. 2013 Apr 11;368(15):1408-16
pubmed: 23574119
Best Pract Res Clin Haematol. 2023 Mar;36(1):101449
pubmed: 36907639
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Int J Hematol. 2018 Feb;107(2):244-250
pubmed: 29030834
Pediatr Blood Cancer. 2023 Aug;70(8):e30401
pubmed: 37158503
Br J Haematol. 2013 Sep;162(6):792-801
pubmed: 23889312
J Natl Compr Canc Netw. 2020 Aug;18(8):1125-1134
pubmed: 32755987
Blood. 2023 Jun 22;141(25):3019-3030
pubmed: 37018730
Pediatr Hematol Oncol. 2013 Sep;30(6):520-31
pubmed: 23802715
JAMA Oncol. 2018 Mar 01;4(3):384-388
pubmed: 29188284
Leukemia. 2022 Mar;36(3):781-789
pubmed: 34675373
Haematologica. 2020 Aug;105(8):2141-2149
pubmed: 31649129
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Clin Oncol. 2010 Sep 1;28(25):3987-93
pubmed: 20679620
Cancer. 2018 Jun 15;124(12):2607-2620
pubmed: 29624648
Br J Haematol. 2019 Jun;185(6):1071-1085
pubmed: 30613948
Br J Haematol. 2005 Dec;131(5):624-7
pubmed: 16351638
Lancet Oncol. 2020 Mar;21(3):421-435
pubmed: 32066543
Ann Hematol. 2016 Aug;95(8):1295-305
pubmed: 27270301
Pediatr Blood Cancer. 2009 Mar;52(3):335-9
pubmed: 18985718
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
J Clin Oncol. 2015 Feb 10;33(5):411-8
pubmed: 25422482
Pediatr Blood Cancer. 2013 Jun;60(6):E19-22
pubmed: 23255383
Blood. 2021 Jul 1;137(26):3595-3603
pubmed: 33684925
J Clin Oncol. 2020 Sep 10;38(26):3062-3070
pubmed: 32552472
Ann Oncol. 2022 Mar;33(3):288-298
pubmed: 34921960
J Clin Oncol. 2022 Jul 1;40(19):2106-2118
pubmed: 35271306
Blood Adv. 2019 Feb 26;3(4):588-595
pubmed: 30792187
Blood. 2013 Jun 20;121(25):5006-14
pubmed: 23589673
Pediatr Blood Cancer. 2004 May;42(5):438-44
pubmed: 15049016
Br J Haematol. 2015 Jun;169(5):711-8
pubmed: 25817915
J Exp Med. 2018 Jan 2;215(1):319-336
pubmed: 29263218
Best Pract Res Clin Haematol. 2023 Mar;36(1):101446
pubmed: 36907642
Br J Haematol. 2015 Mar;168(6):835-44
pubmed: 25395120
Blood. 2014 Jan 16;123(3):334-7
pubmed: 24297868
Pediatr Blood Cancer. 2012 Dec 15;59(7):1229-33
pubmed: 22488718
N Engl J Med. 2018 Aug 30;379(9):856-868
pubmed: 30157397
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626

Auteurs

Nader Kim El-Mallawany (NK)

Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.

Sarah Alexander (S)

Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.

Mark Fluchel (M)

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington, USA.

Robert J Hayashi (RJ)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, Siteman Cancer Center, St. Louis, Missouri, USA.

Eric J Lowe (EJ)

Children's Hospital of The Kings Daughters, Department of Pediatrics, Division of Pediatric Hematology-Oncology, Norfolk, Virginia, USA.

Lisa Giulino-Roth (L)

Department of Pediatrics, Weill Cornell Medical College, New York, New York, USA.

Birte Wistinghausen (B)

Center for Cancer and Blood Disorders and Center for Cancer and Immunology Research, Department of Pediatrics, Children's National Research Institute, Children's National Hospital, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.

Michelle Hermiston (M)

Department of Pediatrics, University of California, San Francisco, California, USA.

Carl E Allen (CE)

Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.
Baylor College of Medicine, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH